Orange, CA 的 肺癌 臨床試驗
14 項針對 肺癌 的研究正在 Orange（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
招募中3 期
- University of California, Irvine Health, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
招募中2/3 期
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- UC IRVINE Health, Orange
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
招募中
- Primary Care & Internal Medicine Services, Orange
- UCI Chao Family Comprehensive Cancer Center, Orange
- UCI Health SeniorHealth Center -Pavillion 4, Orange
- 還有 1 項
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
招募中3 期
- Providence St. Joseph Hospital, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
招募中觀察性研究
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
招募中2 期
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
招募中2 期
- University of California, Irvine Medical Center, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
招募中2 期
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Orange
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
招募中
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
其他城市的 肺癌 試驗
- Houston, TX78 項研究
- Boston, MA62 項研究
- New York City, NY60 項研究
- Los Angeles, CA45 項研究
- Arlington, VA41 項研究
- Washington, DC41 項研究
- Chicago, IL41 項研究
- Nashville, TN40 項研究
- Baltimore, MD40 項研究
- St. Louis, MO39 項研究
- Columbus, OH37 項研究
- Philadelphia, PA36 項研究
Orange 的其他研究
- 非小細胞肺癌25 項研究
- 轉移性癌症20 項研究
- 大腸直腸癌16 項研究
- 卵巢癌16 項研究
- 胰臟癌15 項研究
- 黑色素瘤14 項研究
- 肝癌（肝細胞癌）14 項研究
- 乳癌14 項研究
- 前列腺癌14 項研究
- 胃癌13 項研究
- 癌症（所有類型）13 項研究
- 急性髓系白血病13 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。